Today: 30 June 2026
Browse Category

Health News 20 August 2025 - 10 December 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna, Inc. closed today as one of the more talked‑about healthcare names on Wall Street, with the stock rebounding sharply after a bruising year of falling COVID-19 vaccine sales, pipeline setbacks, and rising regulatory risk. Today’s move comes as investors digest a huge, real‑world French study supporting the long‑term safety and effectiveness of mRNA COVID vaccines, fresh details of a $1.5 billion loan deal, and updated guidance pointing to a slow path back toward growth and eventual profitability. The Chronicle-Journal+1
5 December 2025
··
Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

As of Tuesday, November 25, 2025, Costco is still urging members to stop eating certain ready‑to‑eat Caesar salad products after plastic fragments were found in the dressing packets used in those meals. The nationwide warehouse chain has recalled two popular deli items — its prepared Caesar Salad and Chicken Sandwich with Caesar Salad — in cooperation with dressing supplier Ventura Foods, following a member letter first posted on November 7. cdn.bfldr.com+2EatingWell+2 Today, fresh coverage from outlets in the U.S. and abroad is amplifying the warning, underscoring that some shoppers may still have these products or dressing packets in their refrigerators. Somos Hermanos+2rollingout.com+2
25 November 2025
·
Yoplait YOP Drinkable Yogurt Recall in Canada: Full List of Affected Products, Best-Before Dates and What Shoppers Should Do – November 24, 2025

Yoplait YOP Drinkable Yogurt Recall in Canada: Full List of Affected Products, Best-Before Dates and What Shoppers Should Do – November 24, 2025

Montreal / Ottawa – November 24, 2025 — Canadian parents and yogurt lovers are being urged to check their fridges after a nationwide recall of Yoplait brand YOP drinkable yogurt over fears that some bottles may contain small pieces of plastic. The recall, led by the Canadian Food Inspection Agency, covers all flavours of 200 mL YOP drinkable yogurt, including several multi-pack formats, sold in grocery stores across the country. The recall has been classified as Class 1, CFIA’s most serious category, indicating a high risk that consuming the product could lead to serious health problems if the contamination is present. Recalls Canada+1
24 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran, its in vivo CRISPR therapy for transthyretin amyloidosis. The FDA’s clinical holds on MAGNITUDE and MAGNITUDE‑2 are still in effect pending a formal hold letter. GlobeNewswire+1 Sell‑side reaction was swift. RBC Capital Markets cut its NTLA price target to $9 from $14, pointing to the patient death and the availability of alternative ATTR treatments as reasons to reassess the program’s risk/benefit trade‑off. Other firms also trimmed ratings and targets following the pause and hold. Investing.com
7 November 2025
···
Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Egg supplies and prices remain the backdrop to this story. 163 million U.S. poultry have died from avian flu since 2022, cutting the egg-laying flock by ~11% vs. 2019 reuters.com. Consumers have seen sticker shock – in some cities eggs cost $8–$10 per dozen reuters.com. This summer’s massive recall is partly why the FDA reclassified it at the top risk level newsweek.com foodnetwork.com. How to stay safe: Food-safety experts stress vigilance with eggs. Salmonella is “a leading cause of foodborne illness” in the U.S. foodpoisoningnews.com. The FDA and CDC advise thoroughly cooking eggs and washing hands/surfaces after handling raw eggs foodpoisoningnews.com newsweek.com. If you have the recalled cartons, throw them out or return them. Retailers and restaurants have been asked to pull these eggs from shelves immediately fda.gov.
22 October 2025
·
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer blood test in South Korea, with rights to expand into Japan and Singaporets2.tech. Samsung Electronics is also participating and plans to explore AI and health-data collaborations with GRAILts2.tech. This marks a major vote of confidence from one of Asia’s largest conglomerates. The partnership is expected to close by early 2026 and gives GRAIL a powerful commercialization partner in key Asian marketstradingview.com. Investors cheered the news. GRAL shares jumped ~13–14% on Oct. 16, touching an intraday record of about $85–$86ts2.tech. Reuters reported the stock hit $85.35, a new high, on that announcementtradingview.com. This one-day pop added roughly $300 million to GRAIL’s market capitalizationts2.tech. Notably, the surge came on a day when broader stock indices and biotech peers were down, underscoring how company-specific the excitement was. The rally also continued a multi-day uptrend fueled by rumors of the Samsung deal leading up to the official confirmationts2.tech.
20 October 2025
···
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close, the stock was at $3.08, up roughly 10% over the past month and far outperforming the broader market investing.com. Year-to-date, Achieve’s performance has been volatile but positive. The stock is up markedly from its summer lows, thanks to a string of encouraging milestones. It briefly dipped in early autumn when one rating agency, Weiss Ratings, maintained a “sell” grade on ACHV marketbeat.com, reflecting cautious sentiment. However, momentum quickly recovered heading into mid-October, buoyed by regulatory progress. With the latest FDA catalyst, Achieve’s share price is now hovering near its highest levels of 2025, and trading volume has spiked as investors digest the news. The company’s market capitalization of about
17 October 2025
··
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly after the rout stocktwits.com. Still, at roughly 40% below its IPO price, the Johnson & Johnson spinoff has seen its market capitalization shrink to about $30–31 billion reuters.com. This dramatic sell-off came despite broader markets being relatively calm – the S&P 500 fell only ~0.6% on Thursday nasdaq.com. In other words, Kenvue’s slump is largely company-specific, not a general market downturn. As of now, year-to-date performance is deeply in the red, a stark contrast to the flat or modest gains for major indices. The stock had already been trending down for weeks before this latest drop, reflecting growing unease around Kenvue’s unique challenges.
17 October 2025
···
INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility’s stock took investors on a wild ride on Oct. 16, skyrocketing almost 90% by the closing bellreuters.com. Shares opened at just $0.75 and, in an astonishing surge, hit $1.43 by day’s endreuters.com. To put the move in perspective, INVO’s daily gain far outpaced the broader market, and such a jump is highly unusual – even in the volatile biotech sector. Trading volume exploded to over 108 million sharesreuters.com, dwarfing the typical daily volume and exceeding the company’s entire share float many times overreuters.comstocktitan.net. This indicates a tidal wave of speculative interest flooded into the tiny stock. Market observers noted that nothing fundamentally changed overnight with INVO’s business – instead, the price action seems to reflect momentum trading and sector buzz. Notably, short interest was minimalstocktitan.net, so the rally was not a classic short squeeze forcing bears to cover. Rather, it appears traders piled in en masse, perhaps viewing INVO as an ultra-low-priced play on rising fertility trends. Until Oct. 16, INVO had spent most of October drifting around $0.75–0.80 per sharestocktitan.net. The sudden liftoff caught many by surprise – though micro-cap stocks like INVO are known for extreme volatility, and this isn’t the first time INVO has seen
16 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Koreainvesting.comprnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&Tprnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company advances toward test reimbursement globallyinvesting.comprnewswire.com. Under the LOI, definitive agreements are expected in early 2026, with testing operations to begin soon after closingprnewswire.cominvesting.com. According to Reuters/Investing.com coverage, GRAIL stock “surged 20%” intraday on the newsinvesting.com. The investment price also sets a benchmark valuation – it was about a 15% premium to the prior closing price. Trading platforms noted that with this move, GRAIL had risen more than fourfold year-to-datetradingview.com. The Samsung pact comes on the heels of GRAIL’s earlier expansion deals: in mid-2025 GRAIL teamed up with Everlywell to make Galleri available via prescription on Everlywell’s platformprnewswire.com, and Rush University began offering Galleri testing under
16 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading to roughly $0.36 on the cancer data announcement benzinga.com benzinga.com. That rally brought the stock briefly near its 30-day resistance around $0.26 ainvest.com. Before this spike, GNPX had been trading around $0.20. Over the last five trading days the stock was up about 25.6%, although year‐to‐date it was still down roughly 70% benzinga.com. For context, GNPX’s 52-week high is ~$4.09 and its 52-week low is about $0.22 google.com benzinga.com. Trading volumes have surged: approximately 15 million shares traded Oct 14 stockinvest.us. Market data show roughly $11M market cap after the rally benzinga.com. Technical indicators suggest oversold conditions and a short-term bounce, but heavy resistance near $0.27–$0.29 ainvest.com. Backtests warn that past 25–30% spike days have often been followed by pullbacks ainvest.com. In short, GNPX remains a volatile small-cap biotech: the recent surge is notable, but the stock is still far below prior highs.
15 October 2025
···
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences’ stock has been on a wild ride in early October 2025. Heading into this period, SPRB was a little-known micro-cap biotech trading in the high single digits. At the close on Oct 3, 2025, shares stood at $8.82stocktitan.net after a period of relatively low activity. That calm shattered on Oct 6, when news of an FDA breakthrough designation sent the stock skyrocketing. SPRB opened the day with a huge gap up and at one point surged by 250–300% intraday, hitting roughly $31–$32 per sharebenzinga.comstocktwits.com. Benzinga reported Spruce trading around $31.50 by midday on the 6thbenzinga.com, and Stocktwits noted an extreme burst of bullish sentiment as the stock more than quadrupled at one pointstocktwits.com. This explosive move marks a dramatic reversal of fortune for SPRB. Prior to the rally, the stock had been languishing after a tough 2024–2025 period. Even with a 1-for-75 consolidation, shares were relatively stagnant around the $8–$10 range. Year-to-date, Spruce was actually up about 98% just before the breakthrough newsfinance.yahoo.com – reflecting how beaten-down the stock was coming into 2025 and the modest recovery after restructuring. The Oct 6 spike, however, propelled SPRB to new heights, putting it well above its levels from a year
6 October 2025
··
‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

“Stratus” is the colloquial name for XFG, a recombinant Omicron descendant. WHO added XFG to its monitoring list in late June and, based on available evidence, concluded the “additional public‑health risk … is low.” WHO’s lab summary notes spike‑protein changes that can modestly increase immune escape compared with earlier JN.1‑family strains. World Health Organization Globally, XFG gained speed over the summer. WHO’s dashboard reports XFG was ~67% of submitted sequences in the week ending 31 Aug 2025; the runner‑up, NB.1.8.1, accounted for ~21%. datadot
28 September 2025
Possible Life on Mars, ‘Black Hole Stars’ and a Global Diabetes Bombshell – Science News Roundup (Sept 15–16, 2025)

Possible Life on Mars, ‘Black Hole Stars’ and a Global Diabetes Bombshell – Science News Roundup (Sept 15–16, 2025)

In a sensational development for astrobiology, NASA announced that Perseverance has collected a Mars rock sample that “could preserve evidence of ancient microbial life” nasa.gov. The rover drilled the sample, nicknamed “Sapphire Canyon,” from an ancient riverbed formation rich in clay – exactly the kind of environment that on Earth traps and preserves organic remains nasa.gov nasa.gov. Inside the rock, scientists detected certain organic molecules and chemical patterns that are considered potential biosignatures, meaning they might be remnants of past life nasa.gov nasa.gov. Acting NASA Administrator Sean Duffy hailed the finding as “the closest we have ever come to discovering life on Mars”, calling it a “groundbreaking discovery” that advances our understanding of the Red Planet nasa.gov. Researchers emphasize that further analysis is needed to confirm any biological origin of the compounds nasa.gov. The tantalizing sample will eventually be returned to Earth by a future mission for in-depth lab studies. Still, the mere identification of organics in ancient Martian clay is exciting. Clay and silt sedimentary rocks are excellent at preserving microfossils on Earth, and Perseverance’s instruments found this Martian clay “rich in organic carbon” and other ingredients that could support life’s chemistry nasa.gov. NASA associate administrator Dr. Nicky Fox
16 September 2025
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org. Another study this week revealed a promising cardiovascular benefit from vaccination. An analysis presented at the European Society of Cardiology Congress found that getting the shingles vaccine is associated with significantly lower rates of heart attacks and strokes reuters.com. Pooled data from nine studies
30 August 2025
····
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people with certain medical conditions are cleared for the updated vaccines, and emergency use authorizations for routine use in healthy children were removed realeconomy.rsmus.com. Health experts immediately sounded alarms: the Infectious Diseases Society of America blasted the “narrowed” booster rollout as contrary to scientific guidance and a risk to lives cidrap.umn.edu. They warn these restrictions could hinder access, especially for children, and leave vulnerable groups exposed heading into respiratory virus season realeconomy.rsmus.com. Despite the controversy, U.S. health authorities insist the targeted approach is appropriate while uptake of prior boosters was low. All eyes are now on the CDC’s recommendations and whether insurers will cover off-label use to broaden protection. FDA Snubs Wet AMD Drug – Again: Small biotech Outlook Therapeutics suffered a crushing blow on Aug. 28 when the FDA issued a complete response letter rejecting its eye drug Lytenava for wet age-related macular degeneration fiercepharma.com fiercepharma.com. It was Outlook’s second attempt to repurpose Roche’s Avastin for ophthalmic use, but regulators cited a “lack of evidence of
29 August 2025
·
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket and quote ts2.tech ts2.tech; Allos Pharma press release on arbaclofen rights & Dr. Carpenter quote allospharma.com allospharma.com; Allos press – ASD trial results allospharma.com; BiopharmaDive on VC funding and Kriya Therapeutics raise ts2.tech; Neurology Live – Hearing aids & dementia study ts2.tech ts2.tech; NIH news – Phantom limb cortical maps ts2.tech ts2.tech; WHO/UN joint release – Gaza famine declaration who.int; WHO/WMO report on heat stress who.int; Drug Target Review – Chikungunya outbreak global spread drugtargetreview.com drugtargetreview.com; KFF Health News/Washington Post – CDC layoffs & HHS staff letter kffhealthnews.org kffhealthnews.org.
23 August 2025
·······
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Sources: Key information in this report is drawn from reputable industry and news outlets including Reuters reuters.com reuters.com, Fierce Biotech/Pharma fiercebiotech.com fiercebiotech.com, Endpoints News, STAT, and official statements from organizations like the FDA, EMA, WHO, and leading medical journals. For full details and additional context, please refer to the cited sources inline.
20 August 2025
·····
1 2 3 4

Stock Market Today

  • Rocket Lab Jumps After Striking $8 Billion Iridium Buyout
    June 29, 2026, 10:59 PM EDT. Rocket Lab Corp. (NASDAQ:RKLB) shot up 15.93% and ended at $98.01 after announcing an $8 billion takeover of Iridium Communications Inc. The combined cash and stock deal puts Iridium's value at $54 a share, 24% over its previous close. Rocket Lab says it's moving to create an integrated space business by adding Iridium's satellite network to its launch services. CEO Peter Beck said the plan is to use Iridium's infrastructure alongside Rocket Lab's production and launch capability to go after more markets and build out space applications. Deal completion is targeted for mid-2027, pending shareholder and regulatory sign-off. Rocket Lab's push into satellite communications comes as the sector keeps consolidating.
Go toTop